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ENGLISH SUMMARY 
The incidence of atrial flutter is higher in patients with obesity, hypertension and 
diabetes mellitus and increases with age. With the aging of the general population and 
the increased prevalence of lifestyle disease, such as obesity, hypertension and 
diabetes mellitus, the prevalence of atrial flutter is expected to increase in the years to 
come. Contrary to atrial fibrillation (AF), the thromboembolic and mortality risks 
associated with atrial flutter are sparsely investigated.  
The overall aim of this PhD dissertation was to examine the thromboembolic and 
mortality risks associated with atrial flutter compared with those of AF. First, we 
conducted a systematic review of the current literature investigating the 
thromboembolic risk associated with atrial flutter, and second, we investigated the 
thromboembolic and mortality risks in atrial flutter compared with AF after an 
ablation procedure in a Danish nationwide cohort. Third, we investigated the risk of 
death and development of heart failure and new arrhythmia after an atrial flutter 
ablation procedure.  
The systematic review included both retrospective and prospective studies. From this 
review, we could conclude that patients with atrial flutter had a high risk of 
thromboembolic events. In the nationwide cohort studies, we found 1,096 (33%) 
patients with an incident atrial flutter and 2,266 with an incident AF ablation 
procedure between 1 January 2000 and 31 December 2013. We found a non-
significant increase in the risk of thromboembolic events (hazard ratio (HR) 1.34, 95% 
confidence interval (CI) 0.71-2.41), heart failure (HR 1.14, 95% CI 0.76-1.71) and 
development of a new arrhythmia. However, there is a significantly higher mortality 
risk (HR 1.85, 95% CI 1.29-2.66) in patients with atrial flutter than in AF patients 
after an ablation procedure. In patients who developed heart failure there was a 
significant increase in mortality risk in patients with atrial flutter (HR 2.97, 95% CI 
1.11-7.91).        
In conclusion, in the literature we found an elevated risk of thromboembolic events in 
patients with atrial flutter. In a Danish cohort, we found a higher all-cause mortality 
in patients with atrial flutter than in AF patients after an ablation procedure. The risk 
of developing heart failure or a new arrhythmia was similar between atrial flutter and 
AF. 
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DANSK RESUME 
Patienter med overvægt, forhøjet blodtryk og sukkersyge har øget risiko for at udvikle 
atrieflagren, og forekomsten stiger med alderen. Med højere levealder og øget 
forekomst af livsstilssygdomme som overvægt, forhøjet blodtryk og sukkersyge 
forventes forekomsten af atrieflagren at stige de næste mange år. Modsat atrieflimren 
(AF) er risikoen for apopleksi og død ved atrieflagren sparsomt undersøgt. 
Hovedformålet med denne ph.d.-afhandling, der er baseret på tre studier, var at 
undersøge risikoen for apopleksi og død hos patienter med atrieflagren og at foretage 
en sammenligning overfor patienter med AF. Det første studie var en systematisk 
gennemgang af den tilgængelige litteratur med henblik på at undersøge 
sammenhængen mellem apopleksi og atrieflagren. Det andet studie undersøgte 
risikoen for apopleksi og død efter ablation for atrieflagren og AF i en dansk kohorte. 
Det tredje studie undersøgte udviklingen i død, hjertesvigt og risikoen for ny arytmi, 
baseret på data fra det andet studie.  
Den systematiske litteraturgennemgang indeholdt både pro- og retrospektive studier. 
Ud fra gennemgangen kunne vi konkludere, at patienter med atrieflagren har en 
relativt høj risiko for apopleksi. I de danske kohortestudier identificerede vi 1096 
patienter med atrieflagren (33%) og 2266 patienter med AF patienter behandlet med 
ablation i perioden mellem 1. januar 2000 og 31. december 2013. Vi fandt en ikke-
signifikant stigning i risikoen for apopleksi mellem atrieflagren og AF (hazard ratio 
(HR) 1,34, 95% konfidens interval (CI) 0,71-2,41), hjertesvigt (HR 1,14 95% CI 0,76-
1,71) og ny arytmi, men en signifikant øget risiko for død (HR 1,85 95% CI 1,29-
2,66) hos patienter med atrieflagren. Hos de der udviklede hjertesvigt efter ablation, 
havde patienter med atrieflagren en signifikant øget risiko for at dø (HR 2,97, 95% CI 
1,11-7,91). 
Samlet set viste litteraturgennemgangen en øget risiko for apopleksi hos patienter med 
atrieflagren, og i de danske kohorte studier fandt vi større risiko for død efter ablation 
hos patienter ablateret for atrieflagren sammenlignet med AF ablation. Vi fandt en 
ikke-signifikant stigning mellem atrieflagren og AF i risikoen for apopleksi, 
hjertesvigt og ny arytmi efter ablation. 
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INTRODUCTION 
Atrial fibrillation (AF) is the most common cardiac arrhythmia with an incidence rate 
of 4.3 per 1,000 person-years (1) with a lifetime risk of development of approximately 
25 percent in people ≥40 years of age (2). AF is an independent risk factor for stroke, 
thromboembolism and death (3,4). However, less is known about the related 
supraventricular arrhythmia, atrial flutter and thromboembolic risk. Atrial flutter is 
the second most common cardiac arrhythmia (5) with an overall incidence of 88 cases 
per 100,000 person-years in the general population (6). The age-specific incidence 
rate increases with age, to 587 per 100,000 person-years among individuals above 80 
years (7). While no data have been published on atrial flutter prevalence in Denmark, 
the estimated number of US inhabitants with atrial flutter was 0.07 million in 2005. 
With approximately 200,000 incident cases per year in the US (8), the prevalence is 
expected to increase to 0.15 million by 2050 (9). 
Increasing age and obesity are associated with the risk of development of atrial flutter 
(10). Furthermore, male sex, heart failure, chronic obstructive pulmonary disease, 
diabetes mellitus, and myocardial infarction also increase the risk of atrial flutter 
(7,8,11). Large population-based studies have demonstrated that patients with atrial 
flutter have a high burden of cardiovascular co-morbidity, and that these patients are 
often hospitalized with cardiovascular as well as non-cardiovascular diseases (12). 
The most commonly related admission diagnoses are major bleeding, stroke or 
transient ischemic attack (TIA), congestive heart failure, and other cardiac 
complications (13,14). 
As the general population gets older, with increasing co-morbidity, the optimal 
treatment with the lowest risk of adverse outcomes should be pursued. However, there 
are no large studies investigating the association of atrial flutter with the risk of 
thromboembolism and mortality compared with AF. 
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BACKGROUND 
HISTORICAL PERSPECTIVE 
In the late 19th century, the first description of atrial flutter, or auricular flutter as it 
was termed, was published. McWilliam (15), who conducted animal experiments, 
stated that “The movements are regular; they seem to consist of a series of 
contractions originating in the stimulated area and hence spreading over the rest of 
the tissue”. Later in the early 20th century, when primitive electrocardiograms 
evolved, the sawtooth waves in the inferior electrocardiographic leads, later known as 
classical type I atrial flutter, were described (16). These observations were 
complemented in 1913 by Lewis et al. (17)  who, by a combination of epicardial maps 
and electrocardiogram recordings, stated that ”the activation sequence was orderly, 
i.e., the wavefront circulated in either a cranial-caudo or a caudo-cranial direction 
in the right atrium”. They stated that atrial flutter was due to an electrical intra-atrial 
circus movement around the vena cavae. Indeed, in 1947 Rosenbleuth and Garcia-
Ramos (17) demonstrated that creation of a lesion between the vena cavae induced a 
re-entry loop arrhythmia circulating around this lesion. An additional lesion from the 
inferior vena cava to the atrioventricular groove could terminate the arrhythmia, 
suggesting that the true atrial flutter circuit involves the cavotricuspid isthmus. 
However, this intra-atrial re-entry theory was not widely accepted, and several 
publications supported another theory in which a local ectopic focus was responsible 
for atrial flutter (18–21).  
In the following three decades, both re-entry and ectopic focus theories were widely 
investigated (17,22), but it was not until 1970 that the first classification of atrial 
flutter appeared. Puech el al. (22) proposed that atrial flutter should be classified as; 
(I) typical atrial flutter, (II) atypical atrial flutter and (III) impure atrial flutter. This 
classification marked a new era, and in the following two decades, various 
experimental models and small clinical studies confirmed the general mechanism of 
atrial flutter (17,22). Waldo et al. (22) later modified this classification into two 
subgroups; Type I attributed to movement around an anatomic obstacle, and type II 
based on functionally determined re-entry. This classification was valid until 2001, 
when the Working Group of Arrhythmias of the European Society of Cardiology and 
the North American Society of Pacing and Electrophysiology (23) together published 
the current and still accepted classification. In the latest joint guideline from 2003 
(23), atrial flutter is now divided into two major groups; “isthmus-dependent atrial 
flutter” and “non-cavotricuspid isthmus-dependent atrial flutter”.  
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DEFINITION AND PATHOPHYSIOLOGY 
Cavotricuspid isthmus-dependent atrial flutter 
Isthmus-dependent atrial flutter, or typical atrial flutter, is by far the most frequent 
type (24) and includes a macro-re-entrant counterclockwise or clockwise electrical 
rotation around the cavotricuspid isthmus. An area of relatively slow conduction 
velocity exists in the low right atrium, restricted by the tricuspid annulus as the 
anterior barrier and the crista terminalis as the posterior barrier (6,24).  
Non-cavotricuspid isthmus-dependent atrial flutter 
This type is also known as atypical atrial flutter. Atypical atrial flutter is primarily 
caused by macro-entry circuits around barriers such as atrial scars, crista terminalis, 
the mitral annulus or pulmonary veins (23).  
Atrial fibrillation 
It is well known that there is a clinical similarity between atrial flutter and AF, and it 
has even been proposed that there is a pathophysiological similarity (25). However, 
the mechanisms of AF are not fully established, but contrary to atrial flutter, AF is not 
a macro-re-entrant arrhythmia but characterized by chaotic, uncoordinated 
contractions of the atria with rates above 300 bpm. Local micro-re-entry with 
fibrillatory activity, focal electrical activity, multiple propagating wavelets, and the 
autonomic nervous system all seem to interact in the development and perpetuation 
of AF (26,27).  
CLINICAL PRESENTATION  
The clinical presentation of atrial flutter shares the same characteristics as other 
arrhythmias, e.g. dyspnoea, chest pain, palpitations and fatigue, and can also be 
asymptomatic. The acute presentation of atrial flutter may cause impaired cardiac 
function, heart failure, hypotension, and tachycardia-induced myocardial ischemia. 
Untreated persistent atrial flutter may lead to tachycardia-mediated cardiomyopathy 
(28).  
ELECTROCARDIOGRAM 
As tachycardia-related symptoms are often non-specific for the underlying 
arrhythmia, characteristic electrocardiographic findings are mandatory for the 
diagnosis of common atrial flutter. Common atrial flutter typically appears as an 
inverted sawtooth flutter wave pattern, observed in the inferior electrocardiogram 
leads (II, III, and aVF). The atrial rate is from 240 to 340 bpm (29,30). Often, no 
distinct isoelectric period is visible between the flutter ´F´waves. Other types of atrial 
BACKGROUND 
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flutter can be more difficult to determine as the electrocardiographic patterns are 
uncharacteristic, and some have even proposed that “Atypical atrial flutter is defined 
as continuous baseline activity with anything other than typical atrial flutter F-wave 
morphology” (30). Invasive electrophysiology studies are therefore often required to 
confirm the subtype.  
TREATMENT OPTIONS 
Until the 1960s, the only treatment option for atrial flutter was pharmacologic with 
quinidine, digitalis and procainamide (31,32). In 1962, Lown et al. (33) introduced 
the first non-pharmacologic treatment. They described their initial experience of 
direct-current cardioversion in the treatment of atrial flutter. Pharmacological and 
direct-current cardioversion remained the only treatment options until 1986, when 
Klein et al. (34) reported their results of two patients treated with cryosurgical ablation 
in the right atrium, preventing atrial flutter recurrence. This observation led to several 
publications on the technique and results of radiofrequency ablation of typical atrial 
flutter (6,35–37). Peri-procedural complications during atrial flutter ablations are rare 
(<4%), with the most frequent being haematomas, atrioventricular block, pericardial 
effusion and, more rare, as ventricular arrhythmia, cerebral vascular events, 
myocardial infarction and pulmonary embolism (38–42). Radiofrequency catheter 
ablation is now considered first-line treatment with a high acute and chronic efficacy 
and a low complication rate (29,40,43–45). Besides ablation, other treatment options 
include pharmacologic drugs for either rhythm control (procainamide, propafenone, 
flecainide, sotalol, ibutilide and amiodarone) or rate control (beta-blockers, digoxin, 
verapamil, diltiazem and amiodarone) (23,46) and direct-current cardioversion. 
However, ablation is documented to reduce healthcare utilization with fewer 
hospitalizations, better quality of life (23,29,43) and to be superior to pharmacologic 
drugs and direct-current cardioversion in the prevention of recurrent atrial flutter (40).  
INTERNATIONAL GUIDELINES 
There are no separate guidelines for the management of patients with atrial flutter, and 
numerous published articles and current international guidelines do not discriminate 
between the two arrhythmias. In the 2010 European Society of Cardiology (27) 
guideline for AF it is stated that “Antithrombotic therapy is recommended for patients 
with atrial flutter as for those with atrial fibrillation”, but with a low level of 
evidence. Due to the high procedural success rate, around 95%, and a low annual 
recurrence rate, atrial flutter ablation is often considered a curative treatment (47), and 
some even suggest that anticoagulant treatment could be stopped four to six weeks 
after ablation (28,48,49). However, no large randomized controlled trials have 
addressed the long-term thromboembolic risk associated with atrial flutter, and most 
data are derived from case reports as well as echocardiographic and cohort studies, 
and the true thromboembolic and mortality risk thereby remains uncertain. 
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AIMS AND HYPOTHESISES 
The overall aim of this PhD dissertation was to examine the thromboembolic and 
mortality risk associated with atrial flutter compared to AF. 
The specific aims and hypotheses for papers I-III are:  
Paper I  
Aims: To perform an up-to-date systematic review of the literature to investigate the 
association between atrial flutter and thromboembolic events.  
Hypothesis: Patients with atrial flutter have a similar risk of thromboembolic events 
as patients with AF.  
Paper II  
Aims: To investigate whether there is a similar mortality and thromboembolic risk 
following an atrial flutter ablation procedure, compared with an AF ablation 
procedure. 
Hypothesis: There is a similar mortality and thromboembolic risk following stand-
alone atrial flutter ablation compared with an AF ablation.  
Paper III  
Aims: To compare the risk of death and development of new/recurrent arrhythmia 
and/or subsequent heart failure after an atrial flutter and an AF ablation procedure, 
respectively.  
Hypothesis: There is a similar or lower risk of adverse outcomes after an atrial flutter 
ablation procedure than after an AF ablation procedure. 
THROMBOEMBOLISM AND DEATH IN PATIENTS WITH ATRIAL FLUTTER 
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MATERIAL AND METHODS 
The following is a brief description of paper I-III. Paper II and III are based on the 
same data sources and study population and are therefore described together. A more 
detailed description is presented in each paper.  
PAPER I 
Study eligibility and data collection 
Articles included in this review were identified by searching EMBASE and 
MEDLINE databases using MeSH terms such as “atrial flutter” and “stroke”. In 
addition, a manual search was made of references listed in included articles. 
International guidelines and retro- and prospective studies were included, and 
eligibility was assessed based on the PICO components (population, intervention, 
comparator, outcomes) (50). Inclusion criteria were restricted to age >18 years and a 
clear differentiation between atrial flutter and AF. Author, year of publication, study 
design, sample size, distribution of patients with atrial flutter and AF, type (if any) of 
anticoagulant treatment, length of follow-up, results of transthoracic and 
transoesophageal echocardiography, co-morbidities, and thromboembolic events 
were extracted to further analyses. Quality assessment of each study was performed 
by using context-specific methodological aspects with five predefined parameters 
(51). Due to large heterogeneity, a meta-analysis of the included studies was not 
conducted. 
Study characteristics 
Two hundred and ninety-eight articles were identified by a structured as well as an 
unstructured search, and 52 articles were included in the final review (Figure 1). 
Included articles comprise case-reports, international guidelines and observational, 
echocardiographic, cardioversion and ablation studies.  
MATERIAL AND METHODS 
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Figure 1: Flowchart explaining the exclusion process 
 
 
PAPER II+III 
Data sources (Paper II+III) 
Study data were obtained by merging data from three Danish Nationwide registries: 
the Danish Civil Registration System, the Danish National Patient Registry and the 
National Prescription Registry. All three registries hold information on all Danish 
inhabitants and were linked by the patients’ personal and unique identification 
number, given to all Danish inhabitants. The Danish Civil Registration System (52,53) 
contains data on date of birth, sex, vital status, migration, and date of death. Since 
1977, the Danish National Patient Registry (54–57) has registered all hospital 
admissions with a discharge diagnose code and surgical procedure code according to 
the 10th revision of the Internationale Classification of Disease (ICD) since 1995 (54). 
The National Prescription Registry (58) has recorded all prescription medication 
THROMBOEMBOLISM AND DEATH IN PATIENTS WITH ATRIAL FLUTTER 
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redeemed from Danish pharmacies since 1995 and onwards. Prescribed medication is 
coded according to the Anatomical Therapeutic Chemical (ATC) Classification 
System (57,58).    
Study population (Paper II+III) 
All Danish inhabitants between 18 and 75 years, with an incident atrial flutter or AF 
ablation code between 1 January 2000 and 31 December 2013 were included in the 
study. Patients with a prior ablation procedure code, or diagnose code for heart failure, 
ischemic heart disease, pacemaker, valvular heart disease and/or prior 
thromboembolic events were excluded. In addition, patients regarded as not on 
anticoagulant treatment at the time of ablation were excluded (defined as no warfarin 
prescription redeemed 90 days before ablation. Co-morbidity was obtained at baseline 
defined as the date of the ablation procedure.   
Outcomes (Paper II) 
All-cause mortality was the primary endpoint with the combined thromboembolic 
event (ischemic stroke, TIA, or pulmonary embolism) as secondary endpoint. 
Outcomes were measured from ablation until the occurrence of endpoints, emigration 
or end of study period, whichever came first.  
Outcomes (Paper III) 
Outcomes were defined as all-cause mortality, heart failure, or the combined 
arrhythmia management endpoint (new atrial flutter or AF procedure and/or 
pacemaker implantation).  
Statistical analyses (Paper II) 
We used Kaplan-Meier curves to display survival. Cox proportional hazards 
regression models were used to calculate event rates and hazard ratio (HR). HR were 
reported as crude and adjusted estimates.  
Statistical analyses (Paper III)  
We used Cox proportional hazards regression to compare event rates and HR between 
atrial flutter and AF. Kaplan-Meier survival curves display disease-free survival, and 
the Aalen-Johansen estimator was used to calculate the cumulative incidence rates 
under competing risks of arrhythmia management or heart failure. We used a semi-
Markov transition model to compare event rates between atrial flutter and AF and the 
different transition states (Figure 2), and each state and transition were analysed 
separately.  
MATERIAL AND METHODS 
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Data were analysed using Stata (StataCorp. 2013. Stata Statistical Software: Release 
13. College Station, TX: StataCorp LP). 
Figure 2: Transition states from index ablation procedure 
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MAIN RESULTS 
PAPER I 
Fifty-two articles were included in the review: six observational, 15 
echocardiographic, 14 cardioversion, three ablation studies, two case-reports and 
twelve international guidelines. Publication dates span from 1962 to 2014, with the 
majority published after 1990. The six observational studies revealed a trend towards 
an increased risk of thromboembolic events and death in patients with atrial flutter 
(Figure 3). The highest reported thromboembolic risk was reported in 
echocardiographic studies (0% to 6.8%). There was a high prevalence of thrombus in 
the left atrial appendage (0-38%), and all studies reported the prevalence of 
spontaneous echo contrast (21%-28%). Cardioversion studies had the greatest 
publication date span, stretching from 1962 to 2011. The highest incidence of 
thromboembolic events (0-6%) occurred 1-2 days after the procedure. The ablation 
studies reported that the rate of thromboembolic events was reduced from 17.9 per 
1,000 person-years to 13.1 per 1,000 person-years after an ablation procedure. 
Furthermore, the development of AF after atrial flutter ablation nearly doubled the 
risk of thromboembolic events (0.6 vs. 1.1 per 100 person-years). 
  
Figure 3: Forest plot of associations between atrial flutter and stroke and/or all-
cause mortality (Paper I) 
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PAPER II 
A total of 8,170 patients with either an incident atrial flutter or AF ablation procedure 
were identified by the registries. The study population consisted of 1,096 (33%) 
patients with an atrial flutter and 2,266 (67%) patients with an AF ablation procedure. 
The main reasons for exclusion were the lack of anticoagulant treatment at baseline 
(n=2,044) and heart failure (n=963) (Figure 4). Baseline characteristics (Table 1) were 
nearly similar between the two groups; however, there was an overweight of patients 
with chronic obstructive pulmonary disease, prior heart valve surgery and congenital 
heart disease in the atrial flutter group. After an atrial flutter ablation procedure there 
was a higher mortality risk than after an AF ablation (Figure 5). The mortality rate 
was almost two-fold higher (crude HR 1.92, 95% confidence interval (CI) 1.22-3.03) 
in the atrial flutter group during 5 years of follow-up. After multivariable adjustment, 
the higher risk among atrial flutter patients persisted (HR 1.68, 95% CI 1.05-2.69). 
The thromboembolic event rate for atrial flutter was 0.35 per 100 person-years, and 
the risk was similar to that of AF (crude HR 1.34, 95% CI 0.71-2.41). 
Figure 4: Flowchart of study population exclusion (Paper II and III) 
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Table 1: Baseline characteristics of study population (Paper II and III)
  
  Atrial flutter 
(N=1,096) 
Atrial fibrillation 
(N=2,266) 
Sex (male) 868 (79.2%) 1,645 (72.6%) 
Age at ablation, median IQR 61.0 (52.4 - 66.5) 58.9 (51.5 - 64.7) 
Years with diagnosis1, mean (sd) 2.0 (2.9) 2.8 (3.5) 
Hypertension 290 (26.5%) 612 (27.0%) 
Diabetes 61 (5.6%) 82 (3.6%) 
Obesity 51 (4.6%) 86 (3.8%) 
Hyperthyreosis 29 (2.6%) 76 (3.3%) 
Alcoholism 13 (1.2%) 15 (0.7%) 
Renal disease 13 (1.2%) 15 (0.7%) 
Chronic obstructive pulmonary disease 35 (3.2%) 38 (1.7%) 
Cancer diagnosis 87 (7.9%) 134 (5.9%) 
Heart arrhythmia surgery 25 (2.3%) 32 (1.4%) 
Congenital heart disease 36 (3.3%) 19 (0.8%) 
Beta-blocker2 842 (76.8%) 1,685 (74.2%) 
Anti-arrhythmic medication2 506 (46.2%) 1,134 (50.0%) 
Digoxin 313 (28.5%) 520 (22.9%) 
Amiodarone 170 (15.5%) 452 (19.9%) 
Other3 311 (28.4%) 960 (42.4%) 
IQR: Interquartile range 
1Atrial flutter or atrial fibrillation diagnose 
2At least one redeemed prescription < 1 year before ablation 
3Verapamil, sotalol, dronedarone and flecainide  
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Figure 5: Kaplan-Meier survival plot (Paper II) 
 
PAPER III  
Using the same study population (Table 1) as paper II, we included 3,362 patients, 
1,096 (33%) with an incident atrial flutter ablation procedure. There was a lower 
disease-free survival but a higher risk of heart failure and death in the atrial flutter 
group compared with AF (Figure 6). The observed differences between the ablation 
groups occurred after approximately one year following the initial ablation. With an 
average follow-up of 4.6 years, there was an almost two-fold higher all-cause 
mortality risk after an atrial flutter ablation procedure (HR 1.85, 95% CI 1.29-2.66). 
In the atrial flutter group, the event rate for pacemaker implantation was 1.56 per 100 
person-years, and higher compared with the AF group. However, the risk of 
subsequent death after pacemaker implantation was similar between the two groups 
(HR 4.29, 95% CI 0.82-22.4). The transition to heart failure was similar between the 
atrial flutter and the AF group (HR 1.14, 95% CI 0.76-1.71), but a subsequent 
transition from heart failure to death was higher in patients who had an atrial flutter 
ablation as the index procedure (HR 2.97, 95% CI 1.11-7.91). 
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Figure 6: Kaplan-Meier survival plot (Paper III) 
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METHODOLOGICAL 
CONSIDERATIONS 
Some considerations about the methods and limitations of the three studies should be 
acknowledged. In the following, various sources of bias that can affect the 
interpretation of the studies will be discussed. 
Selection issues 
Selection bias may be defined as any aspect of the way subjects are included in the 
study, creating a systematic difference between the compared populations that is not 
attributable to the associations. In an observational study, selection criteria therefore 
mainly affect the generalisability of the results. In studies II and III, we should 
therefore ask ourselves if any systematic difference exists, I) Do Danish patients differ 
from patients ablated in, for instance, other Western countries? II) Is there a systematic 
difference between patients ablated for atrial flutter and patients ablated for AF? 
Regarding the latter, no comparative data exist, but patients ablated for atrial flutter 
in the Danish cohort (paper II and III) were slightly older, included more males and 
had higher co-morbidity and a shorter mean time with the diagnosis (2.0 versus 2.8 
years, respectively) compared with those ablated for AF. This could reflect presence 
of selection bias in the study. Using Cox proportional hazards models gives us the 
possibility of exploring the relationship between the survival of a patient and several 
explanatory variables. This method also takes into account time to event and time to 
censoring. The study populations in studies II and III included all Danish patients with 
an incident atrial flutter or AF ablation procedure in a restricted time-period. In order 
to eliminate competing arrhythmias we excluded patients with a prior ablation 
procedure code. Atrial flutter and AF often co-exist and in the earlier ICD-10 codes 
classification even shared the same code. In order to separate the two arrhythmias for 
this study, the study populations were included by the ablation procedure codes for 
atrial flutter and AF, respectively, as these represent two different ablation procedures. 
The ICD-10 codes for atrial flutter in the Danish National Patient Registry have 
previously been validated with a positive predictive value of 57.5% in men and 29.6% 
in women (59).  
Publication bias 
Sometimes biases apply to a population of studies, rather than to one study, as in 
publication bias (tendency to publish papers showing positive results). We did not 
find any large randomized trials on atrial flutter ablation in our systematic review. 
Some proclaim that randomized trials are the gold standard for treatment efficacy and 
safety assessments. While randomized controlled trials are indeed the gold standard 
in the sense of providing "fair" comparisons, they may not always provide the most 
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relevant comparisons. Well-designed observational studies can address the question 
whether a treatment is beneficial in daily clinical practice, not just whether the 
treatment by itself is beneficial in ideal settings. Furthermore, bias related to the 
selective reporting of outcomes has also been characterized as a serious problem in 
meta-analyses of clinical trials (60,61). The same is true for meta-analyses of cohort 
studies that can be subject to serious bias (62).  
In paper I, a systematic review was conducted, but it is possible that the exclusion 
criteria - such as foreign language - could lead to additional (selection) bias. 
Furthermore, the data in the included articles were dominated by high heterogeneity 
and low quality in terms of follow-up, methodological methods and endpoints. Due 
to the high heterogeneity in study characteristics, it was not feasible to conduct a meta-
analysis. Nevertheless, in order to minimize bias, we conducted the review according 
to the PRISMA statement (50) and assessed the eligibility of the included studies 
based on the PICO components. We applied strict inclusion criteria with predefined 
components, but a major challenge was the lack of differentiation between atrial 
flutter and AF. This could lead to an underestimation of the presence of AF. Finally, 
the publication date span from 1964 to 2014, a period with great progress in the 
understanding, diagnosing, and treatment of atrial flutter.  
There can be other explanations for the discrepancies between outcome data from 
observational studies and those seen in randomized studies (63). For example, 
differences in length of follow-up may result in different conclusions. In addition, 
randomized controlled trials are externally valid only for the type of patients included 
in that trial, and there is a tendency to publish studies with “interesting” and positive 
outcomes. However, this is probably even truer for observational studies.  
Confounding  
A simple definition of confounding is confusion of effects. This is a phenomenon 
resulting from the fact that one feature of study subjects has not been separated from 
a second feature, and has thus been confounded with it, producing bias. Bias creates 
an association that is erroneous, but confounding describes an association that may be 
correct, but potentially misleading. For example: are patients admitted for atrial flutter 
ablation confounded by a risk factor that is not present in patients admitted for AF 
ablation? The factor that creates the bias, or the confounding variable, must be 
associated with both the independent and dependent variables (i.e. with the exposure 
and the disease). Confounding is primarily a parameter related to studies of causality 
and therefore not a major issue in paper II focusing on outcome. However, as this 
study is based on registry data, it leaves open the possibility of residual and 
unmeasured confounding, in addition to misclassification and ascertainment error. As 
an example, atrial flutter ablation was offered to an older and possibly sicker 
population for which the relevant comorbidities are not necessarily captured by the 
registries.  
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In cohort studies like studies II and III, various analytical techniques exist that provide 
ways of adjusting for confounding in the analysis, e.g. stratification and multiple 
variable regression analysis. To minimize the risk of confounding, Cox proportional 
hazards models were used to account for known explanatory variables and time to 
event and censoring. However, where there is confounding, there is also the possibility 
of residual confounding. If measured or unmeasured heterogeneous key risk factors 
are a possible explanation for the association, then 'possible' does not always mean 
'plausible'. Therefore, a cautious choice of methods and principles can ease 
confounding concerns in observational studies using linked healthcare databases (64). 
Based solely upon electrocardiogram findings, atrial flutter diagnosing seems 
challenging and, in some cases, only 55% of the diagnoses are correct (65). In studies 
II and III, arrhythmia management was defined as renewed ablation (atrial flutter or 
AF) and/or pacemaker implantation. Ablation and pacemaker procedure codes were 
used to investigate arrhythmia management. However, this approach does not take 
into account that patients may have various arrhythmias that are not treated by 
ablation. Asymptomatic AF may be underestimated and undertreated leading to a 
higher mortality and thromboembolic risk, but contrary to the results from paper II, 
this should lead to a more similar mortality risk in the atrial flutter group compared 
with the AF group and cannot explain the higher mortality. In conclusion, paper II 
was a study of associations between exposure and outcomes, and the study did not 
fulfil the requirements to answer questions regarding causality (66). In addition, the 
results from paper III should be interpreted very cautiously in terms of causality, and 
prospective follow-up studies, e.g. with loop-recorders, are needed.  
Limitations of the Danish registries 
In the two cohort studies (papers II and III), data were extracted from three Danish 
Nationwide registries which implies some limitations. Main factors affecting the value 
of data from the used registries are: I) completeness of registration of individuals, II) 
the accuracy and degree of completeness of the registered data, III) data accessibility 
and availability, and IV) possibilities of linkage with other data sources (record 
linkage) (67). First, not all patients diagnosed with atrial flutter or AF are registered 
in the Danish National Patient Register, as some cases are managed at the general 
practice level. The diagnoses of atrial flutter and/or AF in Danish registries have 
previously been validated with a combined positive predictive value of 92.6% (59); 
however, by the use of ablation procedure codes, the risk of arrhythmia 
misclassification is reduced due to the nature of the ablation procedure. The primary 
endpoint, all-cause mortality, is somehow an unspecific endpoint and non-informative 
about causation. Data availability and accessibility may also be a problem when using 
registry-based data as the data collection has already been performed. 
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DISCUSSION 
The aim of this PhD dissertation was to investigate the thromboembolic and mortality 
risk associated with atrial flutter compared with AF. The PhD dissertation is based 
upon three sub-studies, and in the following sections, each sub-study will be discussed 
separately.   
Paper I: Atrial flutter and thromboembolic risk: a systematic review 
This systematic review confirms that there is a risk of thromboembolic events, and 
that the presence of left atrial thrombus and spontaneous echo contrast is highly 
prevalent in patients with atrial flutter. The majority of articles included in this review 
were published before 2001, at a time when the use of anticoagulant treatment was 
almost non-existing. It was not until 2001 that international guidelines addressed the 
issue of anticoagulant treatment in atrial flutter patients (68). The recommendation 
was based upon echocardiographic studies revealing low blood flow velocities in the 
left atrial appendage during atrial flutter compared with sinus rhythm, but higher than 
during AF. The elevated risk of thrombus formation with low blood flow velocities is 
supported by the Virchow triad theory (changes in blood flow, changes in the vessel 
wall and changes in the properties of blood) (69). However, as the formation of 
thrombus associated with atrial flutter seems explicable, the thromboembolic risk is 
multifactorial as demonstrated by Arnold et al. (70) who reported no thromboembolic 
events in 122 patients with atrial flutter who underwent a cardioversion procedure 
without anticoagulant treatment. Moreover, the multifactorial cause of 
thromboembolic events is well recognized in AF patients, where the use of different 
risk scores for thromboembolic risk stratification is well-validated (26). No 
randomized trials were included in paper I, and due to the  large heterogeneity and 
low quality of the data, it was not possible to make an exact estimate of the 
thromboembolic risk. Only papers published until October 2014 were included, and 
subsequently seven articles focusing on the risk of thromboembolic events in patients 
with atrial flutter have been published (48,71–75), but still no randomized studies. It 
is noticeable that a recent Framingham substudy (11) identified a higher risk of stroke, 
mortality and myocardial infarction in patients with atrial flutter compared with 
healthy controls. As emphasized in the latest guideline from the European Society of 
Cardiology (27), the recommendation of anticoagulant treatment is based on a low 
level of evidence due to the non-existence of high quality studies. Nevertheless, this 
systematic review, based on observational, echocardiographic and cardioversion 
studies, and later published articles, supports the current recommendation that atrial 
flutter should be treated according to the same risk profile as AF. 
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Paper II: Death and thromboembolic risk after ablation of atrial flutter 
compared with atrial fibrillation: A nationwide cohort study 
Following an ablation procedure, patients with atrial flutter had a higher mortality risk 
than patients with AF. Atrial flutter patients had a mortality rate of 1.08 per 100 
person-years and compared with AF, there was nearly a two-fold higher mortality risk 
(crude HR 1.92, 95% CI 1.22-3.03). The higher mortality risk was not due to a higher 
risk of thromboembolic events, as there was no difference between the two groups 
(HR 1.22, 95% CI 0.62-2.41). The stroke rate of 0.46 per 100 person-years was 
comparable with that of the general population (76) but lower than in other studies 
(77). In comparison, the Framingham Heart study (11) found a stroke rate of 2.8 per 
100 person-years in atrial flutter patients, which is equal to the rate in AF patients. 
Compared with other studies (7,78,79), we included a relatively healthy population, 
and although there were no large differences between the atrial flutter and AF groups 
at baseline, it cannot be dismissed that the atrial flutter group might be older and more 
ill. Indeed, chronic pulmonary disease and heart failure have been found to be 
predictive factors for death in patients with atrial flutter (80). There was a higher 
prevalence of chronic obstructive pulmonary disease in the atrial flutter group (3.2% 
vs. 1.7%), but the mortality risk remained elevated after adjustment for chronic 
obstructive pulmonary disease (HR 1.66, 95% CI 1.01-2.73). The higher mortality 
risk after an atrial flutter ablation observed in our study, differs from similar studies 
that have reported an equal or even lower risk among atrial flutter patients, indeed an 
annual risk of one third of the risk in patients with AF has been reported, (80,81). 
Seara et al. (80) found that the development of AF after an atrial flutter ablation 
increases the subsequent risk of death nearly threefold (HR 2.82, 95% CI 1.88-4.70). 
The development of AF after atrial flutter is well known and documented to be as high 
as 23.1% in a meta-analysis (40), and this could therefore be an explanation for the 
observed higher mortality risk. It could be speculated that atrial flutter patients’ co-
morbidity is multifactorial and not easily captured by a simple regression analysis. 
Moreover, as some clinicians consider atrial flutter ablation to be a curative treatment, 
this may cause an insufficient follow-up. 
Paper III: The risk of death and adverse outcomes after an ablation procedure 
in patients with atrial flutter compared to patients with atrial fibrillation 
This study confirms an increased overall mortality risk in atrial flutter compared with 
AF patients (HR 1.85, 95% CI 1.29-2.66). The difference in HR between paper II and 
III is that paper II follow-up is stopped at 5 years, whereas in paper III, there is a full 
available follow-up. The mortality rate without transition to other states was 1.10 per 
100 person-years. There was a markedly higher risk of pacemaker implantation 
among atrial flutter patients (HR 1.66, 95% CI 1.14-2.41) but no difference in the 
transition to heart failure (HR 1.14, 95% CI 0.76-1.71) compared with AF patients. A 
similar study by Seara et al. (80) found a nearly two-fold higher mortality rate than in 
our study (2.2 per 100 person-years), but contrary to our study, they included patients 
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with ischemic heart disease, prior thromboembolic events and heart failure, which are 
all independent mortality risk factors. Vidaillet et al. (78) found that with a follow-up 
of more than 13 months, there is a similar mortality risk when comparing an atrial 
flutter ablation, AF ablation procedure and matched controls. This contrasts our 
results, where there is a similar mortality risk until one year after ablation. Whether 
this delayed mortality risk is due to new arrhythmias is speculative, but it has been 
shown that the incidence of AF after atrial flutter ablation seems to be time dependent, 
with reported rates of 17-22% after 6 months increasing to 50% after 2 years, and 60-
80% after 4 years (48). In our study, only 155 patients (14.1%) underwent an AF 
ablation after an index atrial flutter ablation procedure. However, asymptomatic or 
subclinical atrial tachyarrhythmia is found to be eight times more common than 
clinical AF in patients without previous atrial arrhythmia after pacemaker 
implantation (82). Furthermore, an AF ablation is a far more complex procedure with 
an inherent higher procedural risk, and physicians may therefore choose not to refer 
elderly, frail patients with comorbidities for ablation.  
Moreover, the elevated mortality risk could be considered procedure-related, as there 
is a higher risk of pacemaker implantation after an atrial flutter ablation procedure 
(42). Nevertheless, when adjusting for early pacemaker implantation (<30 days after 
ablation), the risk remains elevated (adjusted HR 1.85, 95% CI 1.09-3.13). Untreated 
atrial tachyarrhythmia is a known risk factor for the development of heart failure, and 
in observational studies (11), the event rate is 3.6 per 100 person-years and 5.5 per 
100 person-years in a post-ablation population. Although there is no statistically 
significant difference in the transition from index atrial flutter (4%) or AF (2.6%) 
ablation to heart failure (HR 1.14, 95% CI 0.76-1.71), patients who develop heart 
failure after the index atrial flutter ablation had a higher mortality risk (HR 2.97, 95% 
CI 1.11-7.91). In a newly published paper, Expósito et al. (48) reported a mortality 
risk of 15.8% with 5 years of follow-up after a cavotricuspid isthmus ablation 
procedure. Remarkably, the main cause of death was non-cardiovascular in 68.4% 
(13/19) of cases. Whether adverse effects of anticoagulant treatment drive the 
observed higher mortality risk in the present study remains unanswered, and only 
randomized studies can give us a clear answer of that question. 
 
 35 
 
CONCLUSION 
This PhD dissertation provides additional information on the association between 
atrial flutter and mortality from an epidemiological perspective. Based upon the three 
studies, the main conclusions are summarized below 
Paper I 
The presence of spontaneous echo contrast and left atrial thrombus is highly prevalent 
in patients with atrial flutter. The correlation between spontaneous echo contrast, left 
atrial thrombus and subsequent thromboembolic events is, however, multifactorial. 
This review confirms that there is an elevated risk of thromboembolic events 
associated with atrial flutter.  
Paper II 
In contrast to similar studies, we found a higher mortality risk after an atrial flutter 
ablation procedure compared with an AF ablation procedure. The higher mortality 
risk does not seem related to a higher risk of thromboembolic events. 
Paper III 
Patients with atrial flutter have a higher mortality risk than AF patients after an 
ablation procedure. There is no difference in the risk of heart failure development. 
However, a higher mortality was seen in the patients who develop heart failure after 
atrial flutter ablations compared with AF ablation procedures.   
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PERSPECTIVES   
When and whom to offer anticoagulation, remains a challenge. While the 
recommendations regarding AF patients seems well supported, the recommendations 
for atrial flutter patients are unclear. This PhD dissertation has investigated the risk of 
thromboembolism and death after atrial flutter ablation compared with AF from 
several angles. Thus, the result of the systematic review supports the current 
recommendation regarding thromboembolic risk reduction (83). The CHA2DS2-
VASc stroke risk score has been validated for patients with AF (26) but not for atrial 
flutter patients. However, in the future these scores may provide guidance for the atrial 
flutter populations after systematic validation studies in independent populations. The 
initiation and duration of anticoagulant treatment after atrial flutter ablations therefore 
remain debatable, especially in medium to high-risk patients. In clinical settings, atrial 
flutter ablation is generally considered a low risk procedure with a high procedural 
success rate (28,47,75). Rather surprisingly, studies II and III demonstrate an 
increased mortality risk after atrial flutter ablations. While adjusting for a number of 
known mortality risk factors and procedure-related complications, the mortality risk 
in the atrial flutter group remains increased. This PhD dissertation also indicates that 
patients who develop heart failure after an atrial flutter ablation have a higher 
mortality. However, the registry-based design of the studies does not reveal the 
mechanism as we have no data concerning left ventricular ejection fraction, peri-
procedural anticoagulation strategies, the exact cause of death, or other clinical data. 
Regarding the optimal treatment of atrial flutter, especially following cavotricuspid 
ablation, a number of questions remain unanswered. Although cavotricuspid isthmus 
ablation offers a high procedural success rate, many patients will subsequently 
develop AF and thus possess a renewed – or continued – thromboembolic risk. 
Furthermore, studies with implantable cardiac monitors have demonstrated that 
patients have a higher burden of asymptomatic AF following ablation than previously 
anticipated (84). A study using implantable cardiac monitors after atrial flutter 
ablation might therefore provide valuable insight into the burden of post ablation 
arrhythmia and, at the same time, provide information about other types of 
arrhythmias, e.g. concomitant ventricular arrhythmia in patients with heart failure. 
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APPENDIX A. TABLES PAPER II: 
Supplementary table 1: Event counts, rates, and Cox hazard ratios after 5 years 
of follow-up  
 
 
 
  Ablation procedure 
 
Atrial fibrillation Atrial flutter 
Death   
Events (n) 36 38 
Rate, per 100 person-years (95% CI) 0.56 (0.41-0.78) 1.08 (0.78-1.48) 
   
HR (95% CI)   
Crude 1.00 (reference) 1.92 (1.22-3.03) 
Adjusted1 1.00 (reference) 1.68 (1.05-2.69) 
Adjusted2 1.00 (reference) 1.50 (0.92-2.45) 
   
Thrombo-embolic events   
Events (n) 22 16 
Rate, per 100 person-years (95% CI) 0.35 (0.23-0.53) 0.46 (0.28-0.75) 
   
HR (95% CI)   
Crude 1.00 (reference) 1.34 (0.71-2.56) 
Adjusted* 1.00 (reference) 1.32 (0.69-2.55) 
Adjusted** 1.00 (reference) 1.22 (0.62-2.41) 
*Adjusted for: age (restricted cubic spline), sex, hypertension, and diabetes mellitus,  
**Adjusted for: age (restricted cubic spline), sex, hypertension, diabetes mellitus, time with diagnosis (restricted 
cubic spline) and anticoagulant therapy (time-varying: less than 90 days since last warfarin prescription 
redemption).  
HR: hazard ratio; CI: confidence interval, TE: Stroke, transient ischemic attack and pulmonary embolisms.  
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Supplementary table 2: Univariate mortality hazard ratio by baseline 
characteristics  
  
Hazard ratio (95% CI)  
 
Atrial Flutter Atrial fibrillation 
Male sex 1.42 (0.85-2.39) 1.50 (0.85-2.64) 
Age 1.08 (1.05-1.11) 1.06 (1.02-1.09) 
Time with diagnosis  0.96 (0.88-1.04) 0.97 (0.89-1.06) 
Hypertension   1.49 (0.93-2.38) 1.48 (0.85-2.58) 
Diabetes mellitus  1.60 (0.69-3.68) 2.32 (0.92-5.84) 
Chronic obstructive pulmonary disease 1.16 (0.28-4.74) 3.13 (0.98-10.03) 
CI= Confidence interval 
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APPENDIX B. TABLES PAPER III 
Supplementary table 1: Transition rates for each ablation group and adjusted 
hazard ratios (95% confidence intervals) with atrial fibrillation ablation as 
reference group. 
 
 
 
 
 
Transition Rate per 100 person-years  
(number of events) 
Hazard ratio  
(95 % CI)1,2 
 Atrial flutter  Atrial fibrillation  
    
All-cause mortality 1.34 (78) 0.56 (54) 1.85 (1.29-2.66) 
Initial ablation to (n=1,096) (n=2,266)  
T1: Death 1.10 (43) 0.41 (24) 1.85 (1.09-3.13) 
T2: Arrhythmia management 9.23 (360) 16.0 (923) 0.72 (0.63-0.81) 
- Atrial flutter ablation 3.69 (144) 1.76 (102) 2.80 (2.16-3.62) 
- Atrial fibrillation ablation 3.97 (155) 13.20 (763) 0.38 (0.31-0.45) 
- Pacemaker implantation 1.56 (61) 1.00 (58) 1.66 (1.14-2.41) 
T3: Heart failure 1.13 (44) 1.00 (58) 1.14 (0.76-1.71) 
Arrhythmia management to (n=360) (n=923)  
T4: Death 1.16 (20) 0.62 (23) 1.70 (0.91-3.17) 
T5: Heart failure 1.27 (22) 0.92 (34) 1.36 (0.78-2.35) 
Heart failure to (n=66) (n=92)  
T6: Death 7.29 (15) 2.87 (7) 2.97 (1.11-7.91) 
1Atrial fibrillation as reference 
2Adjusted for age, sex, hypertension and diabetes. 
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Supplementary table 3: Table 2 and sensitivity analysis removing patients with 
pacemaker implantation within 30 days after initial ablation and prior heart 
operation.  
 
 
Transition Rate per 100 person-years  
(number of events) 
Hazard ratio  
(95 % CI)1,2 
Hazard ratio  
(95 % CI)1,2,3 
 Atrial flutter  Atrial fibrillation   
     
All-cause mortality 1.34 (78) 0.56 (54) 1.85 (1.29-2.66)  
Initial ablation to (n=1,096) (n=2,266)   
T1: Death 1.10 (43) 0.41 (24) 1.85 (1.09-3.13) 1.83 (1.08-3.11) 
T2: Arrhythmia management 9.23 (360) 16.0 (923) 0.72 (0.63-0.81) 0.73 (0.64-0.83) 
- Atrial flutter ablation 3.69 (144) 1.76 (102) 2.80 (2.16-3.62)  
- Atrial fibrillation ablation 3.97 (155) 13.20 (763) 0.38 (0.31-0.45)  
- Pacemaker implantation 1.56 (61) 1.00 (58) 1.66 (1.14-2.41)  
T3: Heart failure 1.13 (44) 1.00 (58) 1.14 (0.76-1.71) 1.77 (1.23-2.56) 
Arrhythmia management to (n=360) (n=923)   
T4: Death 1.16 (20) 0.62 (23) 1.70 (0.91-3.17)  
T5: Heart failure 1.27 (22) 0.92 (34) 1.36 (0.78-2.35)  
Heart failure to (n=66) (n=92)   
T6: Death 7.29 (15) 2.87 (7) 2.97 (1.11-7.91) 2.86 (1.06-7.68) 
1Atrial fibrillation as reference 
2Adjusted for age, sex, hypertension and diabetes 
3Removed prior heart arrhythmia operation and heart valve surgery 
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